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Unacylated ghrelin (UAG), the most abundant form of ghrelin in circulation, has been
shown to exert cardioprotective effect in experimental cardiopathies. The present study
aimed to investigate the cardioprotective effect of a linear bioactive fragment of UAG
against myocardial ischemia-induced injury and dysfunction in C57BL/6 wild type mice
and the mechanisms involved. Treatments were administered at doses of 100 (UAG),
1,000 and 3,000 (UAG6−13) nmol/kg at 12 h interval during 14 days prior to 30min left
coronary artery ligation and reperfusion for a period of 6 or 48 h. The infarct area was
decreased in a dose-dependent manner at 48 h of reperfusion, with a reduction of 54%
at the highest dose of UAG6−13 tested. Myocardial hemodynamics were improved as
demonstrated by an increase in cardiac output, maximum first derivative of left ventricular
pressure, and preload recruitable stroke work, a load-independent contractility index. Six
hours after reperfusion, circulating levels of IL-6 and TNF-α pro-inflammatory cytokines
were reduced, and the effect was maintained at 48 h for TNF-α. 5′ AMP-activated protein
kinase (AMPK) was activated, while acetyl-CoA carboxylase (ACC) activity was inhibited,
along with a decrease in apoptotic protein levels. In isolated hearts, the effect of UAG6−13
was unaffected by the presence of D-Lys3-GHRP-6, a ghrelin receptor (GHSR1a)
antagonist, suggesting that the peptide acted through a GHSR1a-independent pathway.
The results support the therapeutic application of UAG bioactive peptide fragments
against myocardial ischemia/reperfusion injury.
Keywords: cardiac ischemia/reperfusion, unacylated ghrelin analogs, hemodynamics, growth hormone
secretagogue receptor, tumor necrosis factor-α, interleukin-6, isolated heart
Huynh et al. UAG6−13 Protects Against Myocardial Ischemia/Reperfusion
INTRODUCTION
Ghrelin, an endogenous selective ligand of growth hormone
secretagogue receptor (GHSR), was discovered by Kojima
et al. as the first known circulating octanoylated peptide (1).
The predominant circulating form of ghrelin in circulation
is unacylated in position 3 (unacylated ghrelin–UAG) (2).
In contrast to acylated ghrelin (AG), UAG is devoid of
growth hormone (GH)-releasing activity, orexigenic, adipogenic
and diabetogenic activities; however it shares cardioprotective
effects mediated through a still elusive receptor independent
of GHSR1a (3). Although the mechanism through which UAG
exerts cardioprotection has not been fully elucidated, activation
of pro-survival pathways, in addition to anti-inflammatory
and antifibrotic activities [reviewed in (4)], supports its
therapeutic potential in myocardial ischemia/reperfusion (MI/R)
injury. Indeed, MI/R is associated with intense inflammation,
apoptosis, and ensuing morbidity associated with pathological
remodeling (5, 6).
Structure-activity relationship studies of UAG uncovered the
bioactivity of shorter fragments devoid of serine in the third
position (7). In particular, linear UAG6−13 (Ser-Pro-Glu-His-
Gln-Arg-Val-Gln-NH2) and its head-to-tail cyclic derivative
(cUAG6−13), retain UAG bioactivity in enhancing survival of
pancreatic islets and beta cells and diminishing oxidative stress
and senescence of human circulating endothelial progenitor cells
(7). UAG6−13 blocked streptozotocin-induced diabetes in rats (7),
whereas cUAG6−13 (AZP-531) reduced high fat diet-associated
inflammation and prediabetes in mice (8). Administration of
AZP-531 in mice subjected to transient left coronary artery
ligation (LCAL) at 5min (pre-) and 30min (post-) reperfusion
reduced myocardial infarction through attenuating reperfusion-
elicited oxidative stress and activating pro-survival pathways (9).
The present study aims to investigate the cardioprotective
effect of linear UAG6−13 in reducing MI/R-induced injury
and improving hemodynamic performance and to examine
underlying mechanisms.
MATERIALS AND METHODS
Mice Treatments and Surgery
All experimental procedures were approved by the Institutional
Animal Ethics Committee, in accordance with the Canadian
Council on Animal Care guidelines for use of experimental
animals and to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(A5213-01).
Four-month-old male C57BL/6 mice, bred and maintained
in-house, were used to determine the effect of UAG6−13
pretreatment on myocardial infarct size and myocardial
functional recovery after 30min of ischemia and 48 h of
reperfusion. UAG-treated mice were used as a positive control
group with known cardioprotective effects. Additional groups of
mice were used to investigate the effect of UAG6−13 pretreatment
on inflammatory and/or metabolic critical processes in the
early (6 h) post-reperfusion stage. The isolated perfused heart
model was used to determine whether myocardial GHSR1a was
involved in the cardioprotective effect of UAG6−13 fragment
through pharmacological means, e.g., use of AG receptor
antagonist (D-Lys3-GHRP-6).
MI/R was performed as described previously (10, 11), as
shown in Figure 1A. Briefly, C57BL/6 mice were pretreated
during 14 days by twice daily subcutaneous (s.c.) injections of
UAG (100 nmol/kg), UAG6−13 (1 or 3µmol/kg), or vehicle (0.9%
NaCl). The last dose of these drugs was administered 30min
prior to ligation of the left anterior descending (LAD) coronary
artery and on the following day, where applicable. Mice were
injected intraperitoneally (i.p.) with buprenorphine (0.05 mg/kg)
prior to endotracheal intubation and ventilated using Minivent
mouse ventilator (Harvard Apparatus, Holliston, MA, USA)
during surgery under isoflurane anesthesia. Transient myocardial
ischemia was induced by the insertion of an 8–0 nylon suture tied
over a piece of tubing at 1mm below the edge of atrial appendage.
Lidocaine (6 mg/kg) i.p. was injected just after occlusion and
10min prior to reperfusion to prevent fatal arrhythmias. The
chest cavity was closed using a 6–0 silk suture and the animals
were allowed to recover for 6 or 48 h. Mice subjected to 6 h of
reperfusion were anesthetized with isoflurane and euthanized
by exsanguination. Assessment of the impact of treatments on
myocardial infarction area was performed following re-occlusion
of the original ligation site after 48 h of reperfusion, followed
by injecting 300 µL of KCl (1M) in the subclavian vein and
Evans blue (2%) through the aorta. Analysis was performed
on triphenyltetrazolium chloride (TTC) (1%)-stained slices by
computerized planimetry by an observer blinded to the treatment
protocol (10).
Myocardial Hemodynamics as Assessed
by Conductance Catheter
Left ventricle (LV) function parameters were derived from
pressure-volume (PV) analysis using a miniaturized PV
conductance catheter, as described previously (10). Briefly, a left
thoracotomy was performed at 48 h post-surgery, and a microtip
1.4 Fr PV catheter (SPR 839, Millar Instruments) was inserted
through the LV apex, connected to a transducer system (Millar).
PV signals were recorded at steady-state and during vena cava
occlusion to reduce pre-load transiently. Absolute volume data
were adjusted by inserting the catheter in a cuvette with pre-
defined volume containing heparinized blood at 37◦C at the end
of each experiment and corrected for the parallel conductance
through the hypertonic saline bolus injection method. Data
were analyzed using IOX2 software (EMKA technologies, Paris,
France).
Isolated Perfused Heart Assay
Hearts from anesthetized (3% isoflurane mixed with 100%
oxygen) and heparinized (5,000 U/kg, i.p.) male C57BL/6
mice were isolated and immersed in ice-cold Krebs-Henseleit
bicarbonate buffer containing 118mM NaCl, 25mM NaHCO3,
4.7mM KCl, 1.2mM KH2PO4, 2.5mM CaCl2, 1.2mM MgSO4,
11mM glucose, 8 nM insulin, 1.5mM lactate, 0.2mM pyruvate,
and 0.5mMEDTA, as described previously (11). After pericardial
fat removal, the aorta was cannulated with an 18-gauge cannula,
and the heart was perfused retrogradely in a non-recirculating
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FIGURE 1 | UAG6−13 reduced infarct area following MI/R. (A) Schematic representation of the experimental protocols. (B) Representative photomicrographs of
Evans Blue and triphenyltetrazolium chloride (TTC) double stained midventricular LV slices showing the IA on the anterior section. (C) Bar graphs of % AAR/LV and (D)
IA/AAR after a 2-week pretreatment every 12 h with the last dose administered 30min before myocardial ligation and 48 h reperfusion. Data are mean ± SEM of n = 6
mice per group. **P < 0.01 and ***P < 0.001 vs. vehicle. Scale bar, 1mm.
mode at a constant perfusion pressure of 80 mmHg with
Krebs-Henseleit bicarbonate buffer supplemented with 1.2mM
palmitate in 2% fatty acid-free bovine serum albumin and gassed
with 95% O2-5% CO2. Hearts were subjected to 30min of
aerobic perfusion, followed by 40min of low-flow ischemia (10%
of preischemic flow) and 10min of reperfusion. Hearts with
rate of perfusion pressure (RPP) <10,000 mmHg/min during
baseline were excluded from the study. AG, D-Lys3-GHRP-6
and UAG6−13 were administered in a non-recirculating mode
via retrograde perfusion throughout the 10min of reperfusion
post-ischemia via a side port directly above the aortic cannula at
final concentrations of 1, 10, and 30µM, respectively. Contractile
function was monitored continuously by means of a fluid-
filled balloon inserted in the LV connected to a pressure
transducer. Ventricular pressures and heart rates were recorded
with a PowerLab/8sp instrument and analyzed with Chart
v5.0.1 software (AD Instruments, Bella Vista, NSW, Australia).
Coronary effluent was collected at various time intervals for
measurements of coronary flow.
Western Blots
LV were homogenized using a dounce homogenizer (TRI-
R S63C, ON, Canada) in PBS containing a protease and
phosphatase inhibitors cocktail (Thermo Scientific Pierce).
Homogenates were separated into two tubes. Total homogenates
were obtained by sonication for 60min on ice with an equal
volume of lysis buffer (150mM NaCl, 100mM Tris-HCl, 2%
Triton X-100, 0.2% SDS, pH = 7.4), centrifuged at 12,000 g for
20min at 4◦C, and the supernatant was kept at−80◦C. To collect
the cytosolic fraction, the other tube was centrifuged at 1,000 g
for 10min at 4◦C, the supernatant was centrifuged at 9,000 g
for 10min at 4◦C, and the supernatant was kept at −80◦C. The
protein concentration was determined by the BCA assay (Pierce
Biotechnology). Equal amounts (25 µg) of protein extracts were
loaded on SDS-polyacrylamide gels and transferred to PVDF
membranes (Bio-Rad Laboratories). After blocking, membranes
were incubated overnight at 4◦C with the following primary
antibodies; polyclonal rabbit anti-Akt and anti-phosphoSer473-
Akt were used for the total homogenates, while polyclonal rabbit
anti-acetyl-coenzyme A carboxylase (ACC), anti-phosphoSer79-
ACC (ACC1 and ACC2), anti-5′ AMP-activated protein
kinase (AMPK)α1/α2, anti-phosphoThr172-AMPK (1:1,000 Cell
Signaling Technology, Danvers, MA, USA), monoclonal mouse
anti-cytochrome c (BD Biosciences, Franklin Lakes, NJ, USA),
polyclonal goat anti-AIF (Santa Cruz, Dallas, TX, USA) were
used for the cytosolic fractions. Monoclonal mouse anti-α-
tubulin (1:5,000, Abcam) was used as an internal control and
detected on the same membrane (Supplemental Figures 2–10).
Membranes were incubated with HRP-conjugated secondary
goat anti-rabbit IgG (1:10,000, Jackson Immunoresearch), goat
anti-mouse IgG (1:10,000, KPL) or donkey anti-goat IgG
(1:10,000, Abcam). Bands from the same blot were detected
by enhanced chemiluminescence and analyzed using ChemiDoc
XRS+ (Bio-Rad, ON, Canada).
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Plasma Cytokines
Blood from non-fasted mice was collected on 4mM EDTA
to determine interleukin-6 (IL-6) and tumor necrosis factor-
α (TNF-α) plasma levels using commercial kits (eBioscience,
Waltham, MA, USA; catalog numbers 88-7064 and 88-7324,
respectively) by following manufacturer’s instructions.
Statistical Analysis
Data are represented as mean ± SEM. Comparisons between
groups were performed using unpaired one- or two-way ANOVA
followed by Student-Newman-Keuls (SNK) method for multiple
post hoc comparisons (GraphPad Prism Version 7.02, San
Diego, CA). Probability values<0.05 were considered statistically
significant.
RESULTS
UAG and UAG6−13 Pretreatments Protect
From Myocardial Ischemia/Reperfusion
Injury and Preserve LV Hemodynamics
C57BL/6 mice were pretreated with UAG, UAG6−13 or 0.9%
NaCl (vehicle) at 12 h interval for 14 days and 30min prior
to LCAL induced by the proximal occlusion of the LAD
coronary artery, followed by 6 or 48 h of reperfusion (Figure 1A).
Our results display a consistently large myocardial area-at-risk
(AAR) (slightly more than 50% of the LV area) in all groups
as shown by representative photomicrographs of TTC-stained
midventricular, transverse slices (Figure 1B). The AAR/LV
ratio did not differ significantly between groups (Figure 1C),
suggesting that the ligation was reproducibly performed at the
same LAD level. We first investigated the cardioprotective effect
of UAG at a dose equimolar to that previously published for
AG shown to exert a cardioprotective effect in experimental
cardiopathies (12, 13). Our results show that prophylactic
administration of UAG (100 nmol/kg twice daily), used as
a positive control, significantly reduced infarct area (IA) to
AAR by 43%, whereas 10–30-fold higher doses of UAG6−13
reduced myocardial infarction to a similar extent (34–54%)
(Figure 1D).
In parallel studies, the effect of a preventive administration of
UAG and UAG6−13 on systemic hemodynamics and indices of
systolic and diastolic function was determined using conductance
catheter-derived PV relationship at 48 h of reperfusion as carried
out previously (10, 11). Vehicle-treated mice exhibited similar
LV dysfunction as those subjected to the same MI/R protocol
(10, 11). Compared to vehicle-treated mice, UAG6−13 improved
systemic hemodynamics by increasing stroke volume and cardiac
output by 40 and 58%, respectively (Table 1). Although systolic
LV indices, including ejection fraction (EF), end systolic pressure
(ESP), and end systolic volume (ESV), were modestly improved
by the peptides at their respective administered doses, stroke
work was increased by 55 and 81% by UAG and UAG6−13,
respectively. The peak rate of rise in the first derivative of left
ventricular pressure (dP/dtmax) was increased by ∼40% by both
treatments as well as that of preload recruitable stroke work
(PRSW), a load-independent indice of contractility, by 49%
TABLE 1 | Hemodynamic measurements at 6 h after myocardial ischemia caused
by a 30min coronary artery ligation in mice.
Treatment
Parameter 0.9% NaCl UAG 100
nmol/kg
UAG6−13 3,000
nmol/kg
BW, g 24.9 ± 0.7 25.5 ± 1.3 25.4 ± 0.7
HR, min−1 400 ± 15 410 ± 15 436 ± 15
SV, µL 10 ± 1 12 ± 1 14 ± 1*
CO, mL/min 4.0 ± 0.4 5.2 ± 0.5 6.3 ± 0.4**
Ea, mmHg/µL 6.3 ± 0.5 6.2 ± 0.6 5.3 ± 0.4
SVR, mmHg min/mL 16 ± 2 16 ± 2 13 ± 1
SYSTOLIC INDICES
EF, % 64 ± 4 77 ± 3** 82 ± 2**
ESP, mmHg 61 ± 3 75 ± 5** 76 ± 3*
ESV, µL 6.5 ± 0.3 4.7 ± 0.3*** 4.5 ± 0.3***
dP/dt max, mmHg/s 4,408 ± 227 5,885 ± 463** 6,517 ± 313***
SW, mmHg µL 505 ± 56 781 ± 82* 916 ± 81**
PRSW, mmHg 49 ± 2 73 ± 5*** 68 ± 4**
Ees, mmHg/µL 8.1 ± 1.3 12.0 ± 2.2 10.2 ± 1.6
Ea/Ees 0.89 ± 0.09 0.57 ± 0.05* 0.61 ± 0.09*
DIASTOLIC INDICES
EDP, mmHg 3.8 ± 0.4 3.9 ± 0.4 3.8 ± 0.6
EDV, µL 14.9 ± 0.5 15.2 ± 0.9 16.8 ± 0.8
dP/dt min, mmHg/s −3,725 ± 218 −5,027 ± 471** −5,479 ± 266**
EDPVR, mmHg/µL 0.35 ± 0.04 0.39 ± 0.04 0.35 ± 0.05
tau, ms 13.3 0.7 11.5 ± 1.2 10.0 ± 0.6*
Mice were randomized to one of three study groups (n = 9-11 per group) and treated
twice per day at 12 h interval. BW, body weight; HR, heart rate; SV, stroke volume;
CO, cardiac output; Ea, arterial elastance; Ees, end-systolic elastance; SVR, systemic
vascular resistance; EF, ejection fraction; ESP, end systolic pressure; ESV, end systolic
volume; dP/dt max (or min), maximal rate of pressure increase (or decline); SW, stroke
work; PRSW, preload recruitable stroke work; EDP, end diastolic pressure; EDV, end
diastolic volume; EDPVR, end-diastolic pressure-volume relationship; tau, time constant
of relaxation (varying asymptote method). Data are mean ± SEM. One-way ANOVA was
applied for comparisons with the Student-Newman-Keuls post hoc comparisons. *P <
0.05, **P < 0.01 and ***P < 0.001 vs. vehicle-treated mice.
(UAG) and 39% (UAG6−13). Reduced tau and increased dP/dtmin
suggested improved diastolic relaxation.
UAG and UAG6−13 Pretreatments Exert
Anti-Inflammatory Effects
We investigated the potential anti-inflammatory effect of UAG
and UAG6−13 peptides in early (6 h) and late (48 h) reperfusion
following myocardial ligation. Our results show that after 14
d pretreatment twice daily, UAG (100 nmol/kg) and UAG6−13
(3,000 nmol/kg) transiently reduced plasma IL-6 levels by 76
and 70% at 6 h, respectively, whereas this effect vanished by
48 h (Figures 2A,B). In a similar manner, substantial inhibitory
effect of treatments was observed on plasma TNF-α levels at
6 h following MI/R, by 43% (UAG) and 62% (UAG6−13). The
inhibitory effect was maintained at 48 h, as shown by a 78% in
UAG-treated, and 46 and 80% reductions in UAG6−13 (1,000 and
3,000 nmol/kg)-treated mice (Figures 2C,D).
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FIGURE 2 | UAG6−13 reduced inflammation following MI/R. Bar graphs represent plasma IL-6 concentration at (A) 6 h and (B) 48 h of reperfusion following a 30-min
LAD ligation. Bar graphs show TNF-α plasma concentration at (C) 6 h and (D) 48 h of reperfusion. Data are mean ± SEM of n = 9–11 mice (6 h time point) and n = 6
mice (48 h) per group. **P < 0.01 and ***P < 0.001 vs. vehicle, δδP < 0.01 vs. UAG 100 nmol/kg and φP < 0.05 vs. UAG6−13 1,000 nmol/kg.
Neither UAG nor UAG6−13 pretreatment modulated body
weight, food or water intake, glycemia, insulin and non-esterified
fatty acid (NEFA) plasma levels (Supplemental Figure 1).
Phosphorylation of Myocardial AMPK, ACC
and Apoptosis-Related Markers After MI/R
in UAG and UAG6−13-Treated Mice
Western blots analysis of LV protein homogenates showed that
the mean relative ratio of pThr172-AMPK to total AMPK band
density was increased by 83% after 6 h reperfusion in ischemic
hearts of mice treated twice daily with UAG6−13 (3,000 nmol/kg),
compared with vehicle-treated mice (Figure 3A). In contrast,
pSer473-Akt to total mean Akt ratio was unchanged compared
to that of vehicle-treated mice at this time-point (Figure 3B).
However, the mean ratio of pSer79-ACC to total ACC was
increased by 91% in both UAG (100 nmol/kg) and UAG6−13
(3,000 nmol/kg)-twice daily treatedmice (Figure 3C). Expression
of mitochondrial signaling proteins of apoptosis, cytochrome c,
and apoptosis inducing factor (AIF), was significantly reduced
in LV cytosolic fraction by UAG6−13 treatment but not in UAG-
treated mice (Figures 3D,E). Complete scanned gels for western
blots are shown in Supplemental Figures 2–10.
UAG6−13 Improves Myocardial
Hemodynamics in Isolated Hearts in a
GHSR1a-Independent Manner
To investigate whether UAG6−13 exerts cardioprotective effect
through a GHSR1a-independent pathway in the heart, we used
an isolated heart model of low-flow ischemia and reperfusion
in Langendorff mode to assess the rate of perfusion pressure
(RPP) and additional hemodynamic parameters. Hearts from 20
mice were sorted according to the following pharmacological
treatments: AG and AG + D-Lys3-GHRP-6, as positive and
negative control groups; UAG6−13 and UAG6−13 + D-Lys
3-
GHRP-6, as tested groups. Our results show that the RPP was
largely preserved in the presence of both AG and UAG6−13
at reperfusion (Figure 4A). Treatment with D-Lys3-GHRP-6
completely abolished RPP rescue by AG at reperfusion; in
contrast, D-Lys3-GHRP-6 did not have any effect on UAG6−13-
elicited cardioprotection. Consistent with improved RPP in the
presence of UAG6−13, myocardial hemodynamics tended to be
improved byUAG6−13 treatment with or without D-Lys
3-GHRP-
6, although no change was observed in heart rate and coronary
flow (Figures 4B–G).
DISCUSSION
The main finding of this study is that a preventive treatment
with a linear UAG fragment, UAG6−13, reduced MI/R-induced
injury and rescued hemodynamic dysfunction in mice, in a
GHSR1a-independent manner. The cardioprotective effects were
associated with potent, time-dependent, and systemic anti-
inflammatory effects of the treatment. These observations are
consistent with those of Harisseh et al. who showed that an
acute administration of cyclic UAG6−13 (cUAG6−13 or AZP-531),
in a similar dose range, reduced infarct size following MI/R in
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FIGURE 3 | UAG6−13 improved cardiac metabolism and reduced apoptosis after MI/R. Bar graphs represent the relative phosphorylated to total protein ratios with
representative immunoblots. (A) pThr172–AMPKα1/α2 (p-AMPK) to total AMPKα1/α2 ratios and immunoblots from cytosolic LV fractions. (B) pSer473-Akt (p-Akt) to
total Akt ratios and immunoblots from total LV homogenates. (C) pSer79-ACC (p-ACC) and total ACC ratios and immunoblots from cytosolic LV fractions.
(D) Cytochrome c (Cyto c) and α-tubulin ratios and immunoblots from cytosolic LV fractions. (E) AIF and α-tubulin ratios and immunoblots from cytosolic LV fractions.
Relative band density ratios were normalized to the vehicle-treated group. Data are mean ± SEM of n = 3 mice per treatment group. *P < 0.05, **P < 0.01, and ***P
< 0.001 vs. vehicle, #P < 0.05 vs. UAG 100 nmol/kg.
mice, as a consequence of an early activation of pro-survival and
anti-oxidative pathways (9).
AG/GHSR1a axis has been proposed as a promising
therapeutic target in a variety of metabolic disorders due to
its pleiotropic effects on appetite, energy metabolism, glucose
homeostasis, and GH release. While the two circulating forms
of ghrelin present distinct endocrine activities (14), they also
share many peripheral biological activities, through the binding
of an as of yet elusive receptor (15–18). Both forms may be
beneficial to rescue myocardial dysfunction elicited by drugs
such as isoproterenol or doxorubicin or ischemia in isolated
hearts, cardiomyocytes and in preclinical models (12, 13, 19–
23). While AG is cardioprotective, its pleiotropic effects and
GH secretagogue activity may jeopardize its favorable effects
in protecting the heart following long-term exposure with the
potential of eliciting serious adverse events such as cancer
growth and metastasis (24). In contrast, UAG, the most
abundant circulating form of ghrelin, shows GH- and GHSR1a-
independent effects in promoting anti-apoptotic pathways in
cardiomyocytes and protecting against drug-induced cardiac
dysfunction and fibrosis (13).
UAG fragments were studied for their bioactivity and ability
to mimic UAG pro-survival effect on beta cells and human
pancreatic islets (7). UAG fragment 6-13 showed cardioprotective
effect (9), and full cyclization of the peptide did not affect
its bioactivity and improved its pharmacokinetics (25). Cyclic
UAG6−13 improved mitochondrial function, reduced apoptosis
andmyocardial damage at 15min and 24 h following reperfusion,
respectively. In agreement, our results show reduced myocardial
damage at 48 h following reperfusion and further show that these
beneficial effects were associated with improved hemodynamics
and reduced plasma TNF-α levels at this time point. In addition,
the anti-apoptotic effect observed by Harisseh et al. (9) after
15min of reperfusion appeared to be maintained at 6 h, a
time point at which changes in myocardial metabolism is
apparent (10). Although the present work does not allow direct
comparison of the cardioprotective efficacy of cyclic and linear
forms of UAG6−13 as experimental designs, doses and endpoints
differed between studies, the present work confirms that the
UAG6−13 fragment is cardioprotective and furthermore, that it
also improves cardiac hemodynamics and contractility, as shown
by a significant increase in cardiac output, dP/dtmax and PRSW.
Both oxidative stress and pro-inflammatory cytokines play
a role in promoting an inflammatory response to MI/R (26).
In the present study, we further investigated the effect of
UAG and UAG6−13 on plasma levels of IL-6 and TNF-α at
6 h of reperfusion, a time point at which myocardial levels
of these cytokines are elevated in humans (27). Our results
show that treatment with UAG and UAG6−13 elicited a striking,
but transient, reduction of IL-6 plasma levels, whereas TNF-
α levels were diminished at both 6 and 48 h after reperfusion.
Of interest, UAG and UAG6−13 shared a similar transient
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FIGURE 4 | UAG6−13 preserved cardiac function in isolated hearts subjected to 40min of low-flow ischemia and reperfusion in a GHSR1a-independent manner.
(A) LV rate-pressure product (RPP) before, during and after reperfusion in the presence of either 1µM AG or 30µM UAG6−13 with or without 10µM D-Lys
3-GHRP-6.
Data are mean ± SEM of n = 4–5 hearts per group. A two-way ANOVA was performed, followed by Student-Newman-Keuls’ post hoc comparisons. There was no
interaction between time and treatment. *P < 0.05 vs. AG + D-Lys3-GHRP-6, by two-way ANOVA followed by Student-Newman-Keuls’ post hoc comparisons,
(B–G) Bar graphs of cardiac hemodynamic parameters at 10 min post-ischemia: (B) RPP, (C) left ventricular–developed pressure, (D) heart rate, (E) dp/dt max, (F)
dp/dt min, and (G) coronary flow. *P < 0.05 vs. AG + D-Lys3-GHRP-6, by one-way ANOVA followed by Student-Newman-Keuls’ post hoc comparisons, #P < 0.05
vs. AG by one-way ANOVA followed by Student-Newman-Keuls’ post hoc comparisons.
inhibitory profile for IL-6 and a prolonged effect on TNF-
α, notwithstanding differences in doses. The reason for the
prolonged effect of the treatment on TNF-α vs. IL-6 plasma
levels is not clear, but might be related to the fact that TNF-
α clearance is four times lower than IL-6 in rats (28). Elevated
levels of circulating inflammatory cytokines, including TNF-
α and IL-6, have been associated with myocardial dysfunction
and increased apoptosis following MI/R (29). Whereas an acute
administration of cUAG6−13 (5min before reperfusion) was
shown to increase myocardial anti-oxidative and anti-apoptotic
pathways at 15min after reperfusion (9), a pretreatment with
linear UAG6−13 (with the last dose administered 30min before
ligation), but not UAG, reduced cytochrome c and AIF protein
expression after 6 h of reperfusion, suggesting that both caspase
dependent and independent pathways have been activated (30).
Our results differ from those of Pei et al. (13) who showed that
UAG, in a similar dose range, administered after doxorubicin
injection in younger (10–12 weeks old) C57BL/6 mice, showed
reduced myocardial apoptosis in treated mice. Yet, it has
been reported that doxorubicin-induced cardiac injury promotes
endogenous ghrelin release, which may thus contribute to the
cardioprotective and anti-apoptotic mechanisms elicited by UAG
in that model (31).
As reported previously for HL-1 cardiomyocytes (22), the
ratio of p-AMPK/AMPK was not significantly changed in UAG-
treated mice, but was increased by UAG6−13 at 6 h of reperfusion,
which may contribute to protect the heart through the
attenuation of TNF-α-elicited apoptosis (32) and/or modulate
myocardial energy metabolism. Along these lines, p-ACC/ACC
was increased by the pretreatments, leading to enhanced β-
oxidation and ATP production (33).Whether myocardial glucose
metabolism was increased and fat metabolism decreased by the
treatments remain to be investigated.
An enigmatic issue about the receptor or receptor subtypes
involved inmediating the effects of UAG andUAG fragments still
remains. In the heart, a number of different receptor subtypes
have been proposed, including ghrelin receptor-like receptor
(GRLR) that would bind ghrelin and UAG as well as UAG
receptors and GHSR1a (34). To investigate whether UAG6−13
exerted its cardioprotective effect via the ghrelin receptor
GHSR1a, we perfused isolated mice hearts with the ghrelin
fragment in the presence or absence of the ghrelin antagonist,
D-Lys3-GHRP-6, a selective antagonist of the AG receptor.
Our results showed that while D-Lys3-GHRP-6 inhibited AG-
induced rescue of RPP, it did not interfere with the effect of
UAG6−13. These observations support that the cardioprotective
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effect on myocardial hemodynamics afforded by UAG6−13, even
at a dose of 30µM, is likely to be mediated by UAG receptors.
In the present study, the effect of UAG6−13 was investigated
in pretreated mice. Although this experimental design may
limit translation to acute clinical situation of MI/R, previous
studies investigating the cardioprotective effect of hexarelin,
a small synthetic growth hormone peptide, required a 7–14
days pretreatment in rats (35). Yet, hexarelin was later shown
to improve cardiac performance by increasing left ventricular
ejection fraction in humans following an acute administration
(36, 37). The cardioprotective effect of a single dose of the linear
octapeptide UAG fragment in mice after the onset of myocardial
ischemia remains to be investigated.
In conclusion, the results of this study show that a
pretreatment with a linear bioactive fragment of UAG reduced
myocardial damage following MI/R and for the first time
shows that these beneficial effects are associated with improved
myocardial hemodynamics, along with potent and prolonged
anti-inflammatory effects over 48 h. These observations add to
the early (15min) anti-oxidative and pro-survival activation
pathways seen with the cyclic peptide (9). Furthermore, we show
that UAG6−13 exerted cardioprotective effects via mechanisms
that are independent of GHSR1a. Taken together, these results
support further studies to investigate the mechanisms and
pharmacokinetics of the peptide for the translation of these
observations.
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